CIT cold ischaemia time 
However use of the DCD/ECD cohort could expand the donor pool by 40% [13] . Interventions that can improve organ viability, and improve function in the peri-operative period during which IR injury is most dominant are potential strategies to better utilise these donor organs [14] Heparin has been used extensively in prevention of thrombosis in transplanted organs in particular kidney and pancreas allografts [15] [16] [17] although the risk of bleeding is significant, and prevention of thrombosis not guaranteed [15] . Therefore, an ideal approach would be a cytotopic that localises within the vasculature of the allograft, exerting an anticoagulant (and thus antiinflammatory) effect locally at the site of the IR response rather than systemically. Manipulating an organ in such a targeted way might negate the need for systemic anti-coagulation and be potentially more effective.
To this aim we have utilized a membrane-associated anticoagulant derived from a minimized form of hirudin, (a known thrombin inhibitor, and naturally occurring peptide in the salivary glands of Hirudo medicinalis leeches). The principle underlying this synthetic cell-tethered inhibitor (Thrombalexin, TLN) [18] is similar to the complement inhibitor Mirococept [4] . TLN binds the cell phospholipid bilayer through a bis-myristoyl hydrophobic structure and a lysinerich sequence [19] , and like hirudin TLN interacts with thrombin at the active site and at the fibrinogen-binding exosite I [20] .
Here in we describe a series of experiments, building on our experience [21] with hypothermic machine perfusion (HMP) to evaluate the potential of ex-vivo organ pretreatment with TLN in ameliorating microvascular coagulation and both macro and micro vascular perfusion deficits in a series of normothermic ex-vivo renal haemo-reperfusion (NHRP) circuits. These experiments
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
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utilised both porcine kidneys, and unused human kidney grafts allocated by NHS Blood and Transplant for research.
Methods: Experiments
Four experiments were conducted and compared TLN to controls. 
Organ Retrieval and Hypothermic Machine Perfusion (HMP)
Kidneys were retrieved from landrace pigs terminated at a local abattoir by stunning and exsanguination. This model of sacrifice was akin to substantial head injury and also DCD as animals were only accessed once cardiac death had occurred. There was a target warm ischaemia of approximately 15 minutes until the institution of cold flush. Access was achieved through a midline laparotomy incision, kidneys were retrieved via en-block dissection, flushed with preservation solution (500-1000ml at 100cmH 2 0) and packed on ice for transport to the laboratory. Paired kidneys were matched between treatment and control groups. Static cold Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
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storage time prior to HMP including transportation was on average 5 hours. All kidneys were perfused initially on a Waters Medical Systems RM3 device for 4 hours of HMP stabilization with UW solution according to clinical protocols [22] .
Human allografts
Approval was granted for research use of human kidney grafts initially retrieved but subsequently not used for transplantation by a National Research Ethics Committee (IRAS code:84202) and NHS Blood and Transplant (the national regulator of organ transplantation in the United Kingdom). One pair of organs were used in this study as part of a direct preclinical model in experiment 4, and underwent identical perfusion protocols as porcine kidneys.
Cytotopic Anti-coagulant

TLN is a conjugate peptide of the direct thrombin inhibitor
Gly-L-Cys-amide] and the cytotopic-tail APT3146 [(N-alpha,-N-epsilon-Bis-myristoyl-Lys-SerSer-Lys-Seryl-Pro-Lys-Lys-Asp-Asp-Lys-Lys-Pro-Gly-Asp-(S-2-pyridyldithio) Cys] [19] . The peptide had a mass of 4649 Daltons as determined by time-of-flight mass spectrometry and was prepared by reaction of the 2 components in aqueous solution followed by further purification [18] . A fluorescently labelled-version, lacking anticoagulant activity (FAM-PTL), was used to study localisation of TLN within the kidney. The component peptides were prepared using solid phase synthesis by Cambridge Research Biochemicals, Billingham, UK and the conjugate also synthesized at scale by Almac Sciences, Craigavon, UK.
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TLN Pretreatment
After HMP stabilization, kidneys underwent pretreatment with TLN. This consisted of 3 distinct 30 minutes hypothermic perfusion episodes (diagrams summarising this protocol and experimental groups can been seen in Figure 1 To provide for an ideal control environment 1 kidney from each pair underwent 'treatment' with TLN while the other served as 'untreated' control.
with porcine whole blood to establish the effect of TLN treatment in a haemo-reperfusion model.
This phase of reperfusion mimics the injury suffered in vivo.
OPS Imaging
OPS (Cytometrics, Inc.; Philadelphia, USA) was used to assess the microcirculation [23] . OPS is based on cross-polarisation of reflected green (548nm) light by oxy-and deoxy-hemoglobin in 
TLN Adherence
Two porcine kidneys and 1 human kidney were treated with a TLN-tail derivatised at the Nterminus with a FAM fluorescent derivative (FAM-PTL) to histologically demonstrate tethering and adherence to the kidney microvasculature.
Statistics
Values are represented as mean and standard deviation. Continuous variables were plotted as the mean area under the curve and evaluated using the paired students T-test or Wilcoxon signed rank test, and repeated measures analysed using ANOVA for repeated measures with Bonferroni correction, as required. Data and statistical analysis was performed using Microsoft® Excel Software (Reading, UK). P value of ≤0.05 was considered significant.
Results
:
Kidney Characteristics
Thirty-eight porcine kidneys and 2 human kidney grafts were utilized and Table 1 summarises porcine kidney characteristics in the experimental groups.
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Hypothermic Machine Perfusion Stabilization
Perfusion characteristics and weight gain in kidneys during initial HMP stabilization were similar between the Protein Treated Groups (PTG1,PTG2,PTG3) and the Control Groups (CG1, CG2, TCG3), and are summarised in Table 2 .
TLN Delivery and Adherence during pretreatment phase
Perfusate samples taken during the "treatment" phase of organ pretreatment from TLN treated kidneys (PTG1, PTG2 and PTG3 Groups) were assessed using a simple clotting assay that indirectly measured the concentration of TLN in the perfusion fluid. These data are shown in Figure 2 . A higher clotting ratio indicates a greater concentration of TLN present in the sample.
In all experiments, the concentration of TLN fell during the treatment phase, consistent with uptake in the kidney. During the washout-2 phase, clotting ratios increased, consistent with washout of non-adherent TLN.
Adherence of TLN
Porcine and human grafts treated with FAM-PTL histologically confirmed tethering and adherence to kidney microvasculature after pretreatment, with continued adherence after 6 hours of NHRP ( Figure 3 ).
NHRP
TLN treated kidney groups demonstrated superior blood flow and PFI compared to the Control Group kidneys ( Figure 4) . Renal blood flow rates were on average 26.4%, 31.7%, and 45%
higher, and PFIs 28.9%, 25.1%, and 42.5% greater in protein treated PTG1, PTG2 and PTG3 kidneys compared to controls.
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Orthogonal Polarisation Spectral Imaging
In Experiment 2 OPS data was recorded and analysed for 4 pairs of kidneys after 6 hours NHRP to assess the microdynamics of the kidney microvasculature. FCD was similar between treated and non treated kidneys however TLN treated kidneys had 44% larger diameter capillaries, 50%
faster RBCv, 3.5 times greater CBFs and PIs compared to the nontreated control kidneys ( Figure   5 ).
Rapid Sampling Microdialysis
Data of cortical micro-dialysis levels were recorded for 4 pairs of kidneys during Experiment 2 during the HMP stabilization phase, and NHRP. During HMP cortical microdialysis lactate concentrations were similar between the nontreated control and TLN-treated kidneys (CG2:
0.128 ±0.006 mM/min vs. PTG2: 0.137 ±0.04 mM/min, p=0.783). In NHRP cortical lactate levels were higher in non-treated vs. TLN-treated kidneys (CG2: 3.28 ±1.04 mM/min vs. PTG2:
1.67 ±0.28 mM/min, p=0.072), with the difference approaching significance ( Figure 6 ).
NHRP Coagulation Analysis
Coagulation data is summarised in Table 2 
Pre-clinical Experimentation with Human Kidney Grafts
A pair of DCD kidney grafts were used in a preclinical model in Experiment 4. CIT was 78
hours (4680 minutes) until start of the experiment. 60.7 ml/min/100g, and PFI: in PTG4: 0.97 ml/min/100g/mmHg vs. CG4: 0.83 ml/min/100g/mmHg. Micro-dialysis lactate concentrations were lower in the control kidney during HMP prior to treatment but were subsequently 36% lower in the treated PTG4 kidney during NRHP. D-Dimer and fibrinogen levels were 2.5-3x higher over the 6 hours of perfusion in the control CG4 group. Percent weight changes, and reperfusion injury demonstrated by light microscopy were similar.
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Discussion:
The increasing use of ECD and DCD organs to expand donor pools means any approach that could ameliorate micro-vascular dysfunction and improve organ perfusion at the reperfusion stage is in high clinical demand. TLN is a novel membrane localising 'cytotopic' anti-coagulant construct that has proven efficacy in improving graft function in murine kidney transplantation models [26] . This is the first study of the pretreatment of large animal organs with this cytotopic anti-coagulant agent using HMP as a delivery vehicle, and further assessing the benefits of this pre-treatment using a NHRP challenge. Using a series of translational porcine ex-vivo renal perfusion and haemo-reperfusion models we demonstrated HMP can be used to deliver TLN into the vasculature of a kidney graft, and facilitates cytotopic tethering and adherence; improving 
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administered systemically [31] . Because thrombin has both procoagulant and inflammatory effects, thrombin inhibition can ameliorate both these sequelae.
Our experiments suggest that TLN anchored to the endothelium can inhibit the activation of clotting. This resulted in superior macro-vascular and micro-vascular perfusion metrics (renal blood flow, PFI) in TLN-treated kidneys compared to the nontreated and Tail-only protein treated controls. Macro-vascular PFI is a useful calculation as it incorporates both renal flow rates and systolic pressure but corrects for differences in kidney mass. In these experiments observed renal blood flow rates and PFIs were between 25-45% superior in the TLN-treated kidneys vs. controls. Relative flow rates during ex-vivo NHRP can be considered indicators of relative organ viability [32] .
Ameliorating the microcirculatory perfusion dysfunction that is seen in renal IR injury in both experimental and clinical settings has been shown to be important and beneficial in improving initial graft function after transplantation, and limiting DGF [33] [34] [35] .
OPS of the microcirculation demonstrated better perfusion in TLN-treated kidneys during the NHRP challenge. The improved calculated microvascular PI (pl/s/mm2) in these kidneys stemmed from larger diameter cortical capillaries, and faster blood flow through these vessels.
The presence of larger calibre vessels can be due to relative vessel dilation [36] secondary to potentially less thrombin action at the endothelial cell surface, and less generation of local vasoconstrictors [37] (eg endothelin) or alternatively more release of nitric oxide (NO).
Alternatively the larger capillaries could be due to less fibrin formation and aggregation of cellular blood components at the endothelial surfaces, rendering better transit through vessels [24] . The larger observed diameter in these vessels may relate to a relative inhibition of Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
dynamic leucocyte aggregation at the endothelial due to less thrombin mediated inflammatory activation, and diminished fibrin generation. Fibrin it-self is known to be a potent proinflammatory mediator [38] .
These changes correlated with the trend for reduced D-Dimer levels during NHRP challenge in TLN-treated kidneys. Although our data approached significance in only 1 experiment this may have been due to confounding effects of the sacrifice used in this uncontrolled DCD model (where a cytokine surge from stunning may render blood more procoagulant), and where DDimers levels are only an indirect measure of thrombin activity.
Faster RBC velocity could be attributed to the relatively lower intravascular clotting activity and less obstruction to flow in capillaries. Maintaining equal systolic perfusion pressures between control and TLN-treated kidneys during NHRP dictates that any observed differences in renal perfusion blood flow dynamics (blood flow rates, PFI) are due to inherent differences in the kidney vasculature and effect of the presence of the cytotopic anti-coagulant proteins. The similar changes in weight in kidneys during HMP and NHRP further indicates that perfusion differences between treated and nontreated grafts are not due to tissue oedema limiting blood flow.
These changes in microcirulatory parameters also associated with lower levels of tissue lactate detected via rsMD in TLN-treated kidneys, most likely reflecting better overall tissue perfusion, both in relative oxygen delivery, and potentially washout of toxic metabolites [39, 40] . The higher variability seen in the control group reflects the variation in graft damage sustained during sacrifice and retrieval, and is an inherent component of an uncontrolled DCD model and may be a reason for the lack of statistical significance.
Furthermore rsMD analysis was available only for 4 pairs of kidneys due to technical difficulties with the rsMD system itself. Localization of the rsMD probes to the cortex was done visually without image guided confirmation introducing the possibility of placement of part of the probe in an alternate region of the kidney parenchyma with differing metabolic profiles to the cortex [25] .
These data complement those obtained in other model systems illustrating the benefits of localised anticoagulation. Inhibition of thrombin in hearts of transgenic mice [41] was associated with complete resistance to acute humoral rejection [42] in a highly stringent xenogeneic model.
Similarly, building on the work of Ding et al [43] , Crikis et al reported improved graft survival of transgenic hearts from mice expressing human thrombomodulin localised to endothelium [44] . In the same study these transgenic mice demonstrated a reduced inflammatory response in stasisinduced thrombosis and a mouse-to-rat xenograft model, with reduced HMGB1 levels in LPS induced endoxtaemia. These reports demonstrate the translational potential of targeting anticoagulants to graft endothelial cells and to inhibit coagulation and inflammation.
Use of appropriate preclinical models is a prerequisite to the development of protocols for clinical introduction. The data obtained from TLN preconditioned human kidneys correlated with our findings in the porcine models. These experiments utilized porcine blood during the NHRP challenge phase, and as evidenced by the progressive increase in fibrin degradation products during NHRP in the control kidneys this combination generated ideal conditions under which the impact of TLN could be studied.
The cytotopic approach suggested here using HMP to deliver TLN is novel and theoretically
ideal. An allograft could undergo HMP at the recipient transplant centre, where TLN would be Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
added to the perfusate, to facilitate tethering and pretreat the endothelium. The allograft would ultimately be transplanted with the thrombin inhibiting anti-coagulants localised to the allograft vasculature, limiting the need for systemic anti-coagulation (with associated bleeding risks) and be potentially more effective. The thrombin inhibiting effects of the TLN would ideally reduce both the procoagulant and proinflammatory actions of thrombin -ameliorating IR responses, and improve postoperative allograft perfusion and function.
Cytotopic painting of the endothelium with TLN can be considered a potential example of 'immunocamouflage' where by the cell membrane surface is modified by nonimmunologic molecules creating a barrier [45] . Although the definitive mechanism of the effect of TLN in this model has not been demonstrated here, it is most likely through inhibition of thrombin by the hirulog sequence contained within; this would be consistent with all in-vitro and ex-vivo testing performed on TLN so far. However, we cannot completely rule out a direct effect due to interaction with the glycocalyx and other membrane associated proteins.
The other caveat to be applied to interpreting this work is that the histological outcomes did not reveal remarkable differences in the treated grafts, and this is likely due to the experimental time frame employed. Despite use of isolated organ reperfusion circuits as well established initial alternatives to in-vivo experimentation the relatively short duration of ex-vivo reperfusion is not a sufficient timescale for development of histological changes that can be seen in-vivo during transplantation [46] with the predominant effects of reperfusion in this model on cellular and molecular processes within the graft. Extending experimentation and reperfusion time would allow further development of histological sequale and the use of a large animal porcine autotransplant model would also allow for functional graft assessment.
Conclusion:
For the first time the pretreatment of kidney grafts with cytotopic therapeutics using HMP, in exvivo porcine and preclinical human kidney perfusion models has been successfully demonstrated, and the presence of these agents improves organ perfusion. There is a high potential for application of this cytotopic technique to clinical practice, not solely for kidney transplantation, but for also for other organs, for example pretreating marginal pancreatic allografts which are very susceptible to reperfusion injury and subsequent allograft thrombosis.
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Methods:
Orthogonal Polarization Spectral (OPS) Imaging OPS has been validated in animal [1] [2] [3] [4] [5] and human models [6, 7] and has been used to investigate changes in the microcirculation in transplantation settings [8] [9] [10] [11] . Images were recorded for ≥2 areas after 6 hours of NHRP in 4 pairs of kidneys. Analysis and quantification of microdynamic parameters was performed offline by frame-to-frame analysis of the recorded images using a computer-assisted image analysis system (CapiScope, KKTechnology, United Kingdom). Analysis included a quantitative assessment of capillary diameters (D), functional capillary density (FCD) and RBC velocity (RBCv). In each sample diagnostic fields (region of interest) each measuring 782x782 µm (0.611 mm 2 ) of interest that were isolated and analysed.
FCD was defined as the ratio of area of RBC perfused capillaries per area of observation (mm 2 ), directly reflecting the state of nutritive tissue perfusion [12] . vRBC (µm/s) was measured in the midpoint of ten capillaries that crossed a designated grid within the ROI by means of frame-toframe analysis (Modification of De Backer's score) [13] . Individual volumetric capillary blood flow (CBF; pl/s) was calculated from RBCv and D metrics according to the formula vCBF = ∏(D/2) x vRBC . To evaluate changes in overall capillary perfusion, a perfusion index (PI) was calculated from using the FCD and CBF metrics (PI = FCD x CBF, pl/s/mm 2 ). The degree of homogeneity (heterogeneity index, HI) in CBF was assessed by expressing the standard deviation (SD) relative to the difference between the maximum and minimum of the CBF (obtained from all observations from 1 experiment at the time point).
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